Home > Riviste > Minerva Urology and Nephrology > Fascicoli precedenti > Articles online first > Minerva Urology and Nephrology 2021 Mar 29

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

 

Minerva Urology and Nephrology 2021 Mar 29

DOI: 10.23736/S2724-6051.21.04217-X

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Oncological outcomes of active surveillance and percutaneous cryoablation of small renal masses are similar at intermediate term follow-up

Paolo UMARI 1 , Michele RIZZO 2, Michele BILLIA 1, Fulvio STACUL 3, Michele BERTOLOTTO 4, Maria Assunta COVA 4, Gianmarco BONDONNO 1, Davide PERRI 1, Giovanni LIGUORI 2, Alessandro VOLPE 1, Carlo TROMBETTA 2

1 Division of Urology, Department of Translational Medicine, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy; 2 Department of Urology, University of Trieste, Cattinara Hospital, Trieste, Italy; 3 Radiology Department, Maggiore Hospital, Trieste, Italy; 4 Radiology Department, University of Trieste, Cattinara Hospital, Trieste, Italy


PDF


BACKGROUND: Active surveillance (AS) and minimally invasive ablative therapies such as percutaneous cryoablation (PCA) are emerging as alternative treatment modalities in the management of small renal masses (SRMs).
METHODS: Fifty-nine patients underwent PCA since 2011 and 75 underwent AS since 2010 at two different institutions. Only patients with follow-up ≥ 6 months were included. All patients were followed with a standardized protocol. Treatment failure was defined by dimensional progression for AS and renal recurrence for PCA, in addition to stage and/or metastatic progression for both groups.
RESULTS: Treatment failure was observed in 14 cases (18,7%) during AS (mainly due to dimensional progression) and 12 patients (16%) underwent delayed intervention with a mean follow-up of 36,83 months. Seven patients (11,9%) in the PCA group experienced treatment failure with a mean follow-up of 33,39 months and 3 of them underwent re-ablation successfully. Cancer-specific-survival at 2 and 5 years was 100% and 95,8% in AS-group vs. 98,2% and 98,2% in PCA-group (p=0,831). One patient in both groups died from metastatic disease. Overall-survival at 2 and 5 years was 91,7% and 82,4% in the AS-group vs. 96,5% and 96,5% in the PCA-group (p=0,113). Failure-free survival at 2 and 5 years was 90,9% and 70,1% in the AS-group vs. 93,1% and 70,9% in the PCA-group (p=0,645).
CONCLUSIONS: AS and PCA provide similar survival outcomes and are safe and valid treatment options for elderly and comorbid patients with SRMs.


KEY WORDS: Active surveillance; Cryoablation; Kidney cancer; Renal cell carcinoma; Small renal masses

inizio pagina